China approves sale of Pfizer’s Paxlovid for COVID treatment, White House says US not involved
The approval came amid an anticipated wave of COVID-19 infections on mainland China.
China has approved the sale of Pfizer’s COVID-19 pill, Paxlovid, to combat a surge of cases on the mainland, marking a rare move for Beijing, normally wary of Western vaccines and medicine.
The approval comes as China races to vaccinate its most vulnerable people in anticipation of a fresh wave of COVID-19 infections. The World Health Organization has raised concerns that China was not adequately vaccinated and the U.S. offered to help.